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Abstract
The presence of autonomic dysfunction in HIV patients is largely unknown. Early studies found autonomic dysfunction in
patients with AIDS. Antiretroviral combination therapy (ART) has dramatically changed the course of the disease and
improved prognosis and decreased morbidity.
Aim: To evaluate whether autonomic dysfunction is present in an ART treated HIV population and if so to identify factors of
importance.
Methods: HIV patients receiving ART for at least 12 months (n=97) and an age-matched control group of healthy
volunteers (n=52) were included. All were non-diabetic and had never received medication for hypertension. Following a
10 min resting period a 15 min ECG recording was performed. Heart-rate variability (HRV) analysis was performed in
accordance with current guidelines and data reported as mean [interquartile range].
Results: Mean normal-to-normal (NN) and total HRV measured as standard deviation of normal-to-normal (SDNN) was lower
in HIV patients compared to controls (905 vs. 982 ms; p,0.001 and 48 vs. 54 ms; p=0.028, respectively). No differences
were found between the groups in parasympathetic activity measured as square root of the mean squared difference of
successive NN-intervals (RMSSD) or the percent of differences between adjacent NN intervals greater than 50 ms (pNN50). In
the HIV positives, haemoglobin A1c correlated inversely with SDNN, RMSSD and pNN50 (p,0.05). Total cholesterol and LDL-
C correlated inversely with RMSSD and pNN50 (p,0.05). Neither HIV duration, HIV-RNA, CD4 cell count nor CD4 nadir
correlated with time or phase domain HRV variables.
Conclusions: Moderate autonomic dysfunction is present in HIV positives patients even with suppressed viral load due to
ART. The dysfunction is correlated with HbA1c and hypercholesterolemia but not to duration of HIV or whether the patients
were receiving protease inhibitors as part of the ART regime.
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Introduction
Various markers have been used to identify autonomic
dysfunction (AD) including decreased heart rate variability
(HRV) and delayed heart rate recovery (HRR) after exercise.
Impaired autonomic function has been found to predict
increased risk for cardiac events and sudden death in patients
with cardiac disease as well as in apparently healthy people
[1–4].
Autonomic dysfunction has been reported in patients with HIV
[5–11]. The prevalence seems to be particularly high in patients
with advanced disease [12,13]. Most studies have been performed
in untreated patients or patients with very advanced disease.
However, the availability of potent combination antiretroviral
regimes (ART) has resulted in a dramatic reduction in HIV-
associated morbidity and mortality [14]. It would therefore be of
interest to study the prevalence of autonomic dysfunction in an
ART treated HIV population. We speculate that suppression of
HIV virus due to ART could reduce the prevalence of autonomic
dysfunction. However, ART is also known to induce an array of
adverse effects, among them dyslipidemia and insulin resistance
[15–17]; and specifically ART regimens including a protease
inhibitor (PI) has been linked to development of hyperglycemia
and hyperlipidemia in some HIV infected patients.
Since diabetes is a known cause of autonomic dysfunction the
diabetogenic effect of ART could cause autonomic dysfunction in
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been associated with development of toxic neuropathy including
nucleoside analogue reverse transcriptase inhibitors as didanosine
and stavudine [18,19].
Therefore, ART associated autonomic dysfunction could in
principal be caused both by the diabetogenic and the neurotoxic
effect among other unrecognized causes.
Recently, in a small pilot study we found indications of existence
of autonomic dysfunction despite optimal treatment of HIV
patients [6]. However, a larger study is needed to confirm these
findings as well as to gain the statistical power that allows for
analysis of possible causative relations, e.g. changes in lipids and
blood glucose as well as influence of different components of ART.
The present study was designed to allow for analysis of such
correlations.
The aim of the present study was therefore to study the presence
of autonomic dysfunction in a population of HIV positive patients
receiving ART. In addition, factors influencing HRV in HIV
positive patients were also studied.
Materials and Methods
Subjects
Between 2004 and 2009 patients and controls were enrolled.
The Danish Scientific Ethical Committee approved the study (No.
H-C-2009-051) and written informed consent was obtained from
all the participants.
HIV patients. A total of 97 patients with HIV infection were
included. The patients were recruited from the outpatient clinic at
the Department of Infectious Diseases, Hvidovre University
Hospital, Copenhagen, Denmark. Eighty-six (83%) were
Caucasians and 11 (11%) were Africans, 6 (6%) were Asian and
1 (1%) Inuit. Inclusion criteria were: (i) age 18 years or older, (ii)
proven HIV infection, (iii) receiving stable doses of ART for $12
months. Exclusion criteria: (i) clinical history of cardiovascular or
ischemic heart disease, (ii) known alcohol abuse, (iii) diabetes
mellitus, (iv) medication for hypertension or (v) pregnancy.
The patients had been HIV positive for median 11.1 years.
Twenty (19%) of the HIV patients had been diagnosed with AIDS.
Patient characteristics including biochemical data are shown in
table 1.
Controls. Fifty-two age and gender matched healthy
volunteers were included. Their basic characteristics are
summarized in table 1. The control subjects were included from
individuals participating in a Danish prospective population study
(Copenhagen Centre of Prospective Population Studies at the
Institute of Preventive Medicine, Bispebjerg Hospital, University
of Copenhagen, Denmark). All were Caucasians.
Heart rate variability testing
Following a 10 min resting period a 15 min ECG recording was
performed while patients were in the supine position. HRV analysis
was performed in accordance with current international guidelines
[20]. The ECG data were sampled by a Holter monitoring recorder
at 250 kHz and analysed by the HolterSoft Ultima soft-ware
(Novacor SA, Cedex, France) that complies with current guidelines.
The time domain analysis variables were: mean normal-to-normal
(NN; units: ms), standard deviation of NN (SDNN; units: ms) and
square root of the mean squared difference of successive NN-
intervals(RMSSD;units: ms)and thepercent ofdifferencesbetween
adjacent NN intervals greater than 50 ms (pNN50). SDNN is
considered an estimate of overall HRV and thus both an indicator
of sympathetic and parasympathetic influence. RMSSD is an
estimate of short-term components of HRV and thus considered
reflecting mainly the parasympathetic influence. Deterministic
analysis was performed as Poincare ´ plot analysis, also known as
Lorenz plot analysis. The variables were: LL (length of Lorenz plot),
LB (width of Lorenz plot) and LSD (difference between geometric
and mass center). LL is considered an indicator of long-term
variability and LB the short-term variability.
Statistical analysis
We performed Kolmogorov-Smirnov test of all variables to test
for assumption of normal distribution. Most of the HRV measures
as well as most of the biochemical markers were not normal
distributed. Accordingly, the data were handled using non-
parametric statistics. Therefore, data are presented as median
with 25 and 75 percentiles in parenthesis. Comparisons between
the groups were performed using Fisher’s exact test for binomial
data (262 contingency tables) and Mann-Whitney test for
continuous data. Correlations were analyzed using non-parametric
(Spearman) correlation and expressed with Spearman’s rho.
P,0.05 was considered significant. P-values between 0.05 and
0.1 was considered borderline significant.
Results
The group of HIV positives did not differ from the control group
withrespecttoage,gender,bodymassindex,systolicbloodpressure,
creatinine and cholesterol (including HDL-C and LDL-C). The
HIV patients as a group had lower haemoglobin, higher blood
glucose and higher triglyceride. The data are summarized in table 1.
The HIV parameters and the ART of the HIV study group are
summarized in table 2. Median duration of HIV was 11.1 years
and median duration of ART was 7 years.
Heart rate variability: Time domain analysis
Mean NN was significantly lower in HIV patients compared to
the controls (905 vs. 982 ms; p,0.001). SDNN was significantly
Table 1. Comparison of study groups.
Control group HIV group Significance
Number of subjects 52 97
Gender (male/female) 43/9 75/29 NS
a
Age (years) 49 (43–56) 46 (40–54) NS
b
Body mass index (kg/m
2) 25 (24–27) 25 (22–27) NS
b
Systolic blood pressure
(mmHg)
123 (116–135) 125 (115–140) NS
b
Diastolic blood pressure
(mmHg)
74 (68–81) 79 (71–89) p=0.03
b
Hemoglobin (mmol/L) 9.1 (8.7–9.2) 8.7 (8.3–9.3) p=0.03
b
Creatinine (mmol/L) 77 (68–81) 73 (66–83) NS
b
Glucose, blood (mmol/L) 5.2 (4.8–5.5) 5.5 (5.1–5.9) p=0.004
b
Hemoglobin A1c (%; DCCT) 5.6 (5.4–5.8) 5.2 (5.0–5.6) p,0.001
b
Cholesterol, total (mmol/L) 5.1 (4.5–5.6) 5.5 (4.6–6.3) NS
b
HDL-cholesterol (mmol/L) 5.1 (4.5–5.6) 1.3 (1.0–1.5) NS
b
LDL-cholesterol (mmol/L) 5.1 (4.5–5.6) 3.1 (2.4–4.0) NS
b
Triglyceride (mmol/L) 5.1 (4.5–5.6) 1.6 (1.0–2.2) p,0.001
b
Values are median (interquartile range).
a) Fishers exact test;
b) Mann-Whitney test.
doi:10.1371/journal.pone.0020196.t001
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p=0.042). No differences were found between the groups
regarding RMSSD and pNN50. Data of the time domain analysis
are summarized in table 3.
Correlation with biochemical parameters. In the HIV
positive group haemoglobin A1c correlated inversely with SDNN
(r=20.234; p=0.027; Fig. 1), RMSSD (r=20.287; p=0.006)
and pNN50 (r=20.299; p=0.003; Fig. 2). In addition, in HIV
positives total cholesterol inversely correlated with RMSSD
(r=20.259; p=0.011) and pNN50 (r=20.237; p=0.021) but
not with mean NN or SDNN. Likewise, LDL-cholesterol inversely
correlated with RMSSD (r=20.262; p=0.012) and pNN50
(r=20.250; p=0.017) but not with mean NN or SDNN. In the
control group no correlations were found between the biochemical
parameters and time domain variables.
Correlation with HIV parameters. None of the HIV
parameters, HIV duration, HIV-RNA viral load, CD4 cell
count or CD4 nadir, correlated with any of the time domain
HRV variables.
Effect of HIV medication. Duration of ART was between
3.6 years and 11.8 years. There was a borderline significant
inverse correlation between ART duration and mean NN
(r=20.171; p=0.093). Of the 97 HIV patients, 33 patients
(34%) received protease inhibitors (PI) whereas 64 (66%) did not.
No difference was found between the group receiving PI and the
one not receiving a PI-sparing regime and mean NN, SDNN,
RMSSD or pNN50. Likewise no difference was found when
patients in ART were stratified on basis of receiving abacavir
(n=55; 57%) or not receiving abacavir (n=42; 43%) in mean NN,
SDNN, RMSSD or pNN50. Only 7 patients received didanosine
and none of the patients stavudine. Thus statistical analyses were
not performed regarding these antiviral drugs typically associated
with development of toxic neuropathy.
Heart rate variability: Poincare ´ plot analysis (phase
domain analysis)
No differences were found between HIV patients and control in
any of the 3 variables LL,L B and LSD. Data on Poincare ´ plot
analysis are summarized in table 4.
Correlation with biochemical parameters. In the HIV
positive group haemoglobin A1c correlated inversely with LB
(r=20.209; p=0.049) but not with LL or LSD. No other
biochemical parameters measured (see table 1) correlated with
LB,L L or LSD. In the control group no correlations were found
between the biochemical parameters and phase domain variables.
Correlation with HIV parameters. None of the HIV
parameters, HIV duration, HIV-RNA, CD4 or CD4 nadir,
correlated with LB,L L or LSD.
Effect of HIV medication. There was a borderline
significant inverse correlation between ART duration and LB
(r=20.188; p=0.066) but not with LL or LSD. No difference was
found in any of the phase domain variables between the group
receiving or not receiving PI. Likewise no difference was found
between patients receiving or not receiving abacavir.
Discussion
The main finding in our study was presence of autonomic
dysfunction in a group of HIV patients with suppressed viral load
due to ART when compared to age and gender matched healthy
HIV negative controls.
We found a decrease in mean NN, i.e. an increased resting
heart rate probably indicating a decrease mainly in parasympa-
thetic tone since it has a strong influence on the resting heart rate.
In addition, a lower SDNN was found in the HIV patients also
indicating an overall decrease in heart rate variability since SDNN
is considered an indicator of overall HRV, i.e. the combined
parasympathetic and sympathetic input. Taken together it
therefore seems likely that at least the parasympathetic input is
blunted. However, the indicators of short-term variability that
normally are considered to primarily reflect the parasympathetic
regulation, RMSSD and LB were not different between the groups
indicating that the dysfunction may not only be parasympathetic.
The present results are in accordance with our previous study of
16 ART treated HIV patients where reduced HRV was found as
well [6]. In studies performed prior to effective treatment regimes
patients with advanced HIV disease showed in general both
sympathetic and parasympathetic dysfunction. The autonomic
dysfunction in untreated patients with advanced disease was
generally believed to be caused by HIV-1 virus itself, which is well
known to be neurotropic [12,21]. Moreover immune suppression
may also be responsible for development of autonomic dysfunc-
tion. However, in our study we did not find any correlation
between measures of HRV and HIV duration, HIV-RNA, CD4
cell count or CD4 nadir. In agreement with this, no statistical
correlation was found between autonomic symptom scores and
CD4 cell count in HIV positive treatment naı ¨ve African patients
[22].
Table 2. HIV parameters of study group (n=97).
Duration of HIV (years) 11.1 (5.8–15.6)
Duration of ART (years) 7.2 (3.6–11.8)
CD4 (cells/mm
3) 552 (434–717)
CD4 nadir (cells/mm
3) 200 (98–260)
ART
3 NRTI 5 (5%)
2 NRTI + 1 NNRTI 59 (61%)
2 NRTI + 1 PI 26 (27%)
1 NNRTI + 1 PI 7 (7%)
Fully suppressed HIV RNA
* 96/97 (99%)
**
Values are median (interquartile range).
ART: Highly active antiretroviral therapy; NRTI: Nucleoside transcriptase
inhibitor, NNRTI: Non-nucleoside transcriptase inhibitor, PI: Protease inhibitor.
*) HIV RNA#400 copies/mL;
**) The remaining patient had viral load=560 copies/ml.
doi:10.1371/journal.pone.0020196.t002
Table 3. Heart-rate variability: Time domain analysis.
Control group
(n=52)
HIV group
(n=52) HIV group
Mean NN (ms) 982 (894–1,103) 905 (850–989) p,0.001
SDNN (ms) 54 (43–72) 48 (37–65) p=0.042
RMSSD (ms) 28 (22–41) 29 (20–49) NS
pNN50 (%) 5 (1–9) 5 (1–20) NS
Values are median (25 percentile-75 percentile).
Mean NN: mean normal-to-normal, SDNN: Standard deviation of NN; RMSSD:
Square root of the mean squared difference of successive NN-intervals; pNN50:
Percent of differences between adjacent NN intervals greater than 50 ms.
Statistical comparison was performed by Mann-Whitney test.
doi:10.1371/journal.pone.0020196.t003
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patients and when treated optimally to obtain continuous
suppression of HIV RNA as well as high CD4-cell counts, which
indicates immune competence. The treatment has decreased
mortality of HIV patients but has also lead to long-term concern
about possible adverse effects of treatment including greater risk
for cardiovascular disease [23]. Adverse effect could be both due to
the drugs themselves, and due to development of hypercholester-
olemia, insulin resistance and metabolic syndrome, well known to
be associated with ART [15–17]. However, in the present study
Figure 1. Correlation between Hgb A1c and standard deviation of NN (SDNN; units: ms) in 97 HIV positive patients receiving
antiretroviral treatment.
doi:10.1371/journal.pone.0020196.g001
Figure 2. Correlation between Hgb A1c and percent of differences between adjacent NN intervals greater than 50 ms (PNN50) in 97
HIV positive patients receiving antiretroviral treatment.
doi:10.1371/journal.pone.0020196.g002
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duration of ART. Since PI’s have been linked to both
hypercholesterolemia and development of insulin resistance, we
also compared HIV patients receiving and not receiving PI as part
of ART. Again, we did not find any difference in HRV measures.
This finding is in agreement with a previous report that found
impaired HRV in HIV positive individuals on ART whether or
not the ART regime included a PI [10]. Recently, also abacavir in
particular has been demonstrated to bear an increased risk of
myocardial infarction [24]. Therefore, we also performed a
comparison of patients receiving abacavir with those not receiving
this drug. No difference in HRV was found.
Since development of autonomic dysfunction may be mediated
via hypercholesterolemia and insulin resistance or hyperglycemia
we compared the HRV parameters with biochemical measures.
Here we found in the HIV group that a clear correlation existed
between hemoglobin A1c and most of the HRV measures
indicating that a high hemoglobin A1c predicted autonomic
dysfunction. As hemoglobin A1c is a good parameter of long-term
blood glucose it seems that high blood glucose is a risk factor in
HIV patients for development of autonomic dysfunction and that
this is a further reason to monitor blood glucose levels closely in
this population. In contrast, no such correlation was found in the
HIV negative group that in general had hemoglobin A1c levels of
the same magnitude and range as the HIV patients. It therefore
seems, that HIV patients somehow are more sensitive than HIV
negatives to elevation in hemoglobin A1c. We have no obvious
explanation for this but negative synergy with other factors in
HIV-positive individuals may be a possible explanation. In future
investigations in-depth study of on glucose metabolism, e.g. oral
glucose tolerance test and measurement of insulin levels could be
included to study the mechanism further. AD is a serious chronic
complication of diabetes and in patients with diabetes-1 random-
ized prospective trials supports a central role for hyperglycemia in
the pathogenesis of AD [25].
Also total cholesterol as well as LDL-cholesterol in the group of
HIV positives correlated in our study with some of the HRV
parameters. A high level of cholesterol or LDL-cholesterol was
associated with decreased autonomic function measured as HRV.
Again, this association was not found in the control group of HIV
negatives even though the level and range of lipids were the same
in the two groups. Therefore, also with regards to hypercholes-
terolemia it seems that it causes more damage to the autonomic
nervous system in HIV patients than in HIV negatives. Again, the
reason is not obvious but may be due to synergy with some other
factors related to HIV disease. Also with regards to cholesterol
levels it therefore seems more important to monitor and treat in
HIV positives than in HIV negatives in order to prevent
development of autonomic dysfunction.
In summary we found that autonomic dysfunction is present in
HIV positives patients with suppressed viral load due to ART
although the degree of dysfunction is moderate in most cases. The
dysfunction is neither related to HIV duration, HIV-RNA, CD4
cell count, C4 nadir or ART duration nor to receiving PIs or
abacavir. However, the dysfunction is correlated with high glucose
levels (hemoglobin A1c) as well as with hypercholesterolemia in
HIV patients but not in HIV negatives. We conclude that tight
monitoring and interventions to obtain euglycemia and normo-
cholesterolemia are particularly important in HIV patients to
avoid development of autonomic dysfunction. Further studies are
needed to elucidate why HIV positives are more sensitive to
changes in glucose and lipids.
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